Trasylol Linked To Increased Long-Term Mortality In CABG Patients – JAMA
Executive Summary
Bayer's Trasylol (aprotinin) is associated with an increased risk of death in the five years following coronary artery bypass graft surgery (CABG), according to a study published in the Feb. 7 Journal of the American Medical Association
You may also be interested in...
Safety Trials In Trasylol ’s Future, But Design Could Prove Challenging
FDA and Bayer will begin discussions of post-marketing studies for the firm's Trasylol (aprotinin) due to suggestive but inconclusive observational data linking the drug to renal events and death
Trasylol Label Should Get Warning, But Not Study Details Advisory Cmte. Says
Following a Sept. 12 advisory committee meeting evaluating safety signals for Bayer's Trasylol (aprotinin), FDA faces the question of how to re-label a drug with uncertain but serious risks
Safety Trials In Trasylol ’s Future, But Design Could Prove Challenging
FDA and Bayer will begin discussions of post-marketing studies for the firm's Trasylol (aprotinin) due to suggestive but inconclusive observational data linking the drug to renal events and death